Synergen Inc. regulatory update

Synergen Inc. (SYGN) SYGN (Boulder, Colo.) filed for marketing approval of Antril Interleukin-1 receptor antagonist to treat severe sepsis in Canada, Denmark, Sweden and Norway. SYGN anticipates comp...